{ "ok": true, "cik": "1704287", "ticker": "BJDX", "name": "Bluejay Diagnostics, Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-08", "items": [ "1.01 Entry into a Material Definitive Agreement", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1704287/000121390026098071/0001213900-26-098071-index.htm" }, { "form": "8-K", "filed": "2026-08-13", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1704287/000121390026088701/0001213900-26-088701-index.htm" }, { "form": "10-Q", "filed": "2026-08-12", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1704287/000121390026088347/0001213900-26-088347-index.htm" }, { "form": "8-K", "filed": "2026-07-22", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1704287/000121390026080474/0001213900-26-080474-index.htm" }, { "form": "8-K", "filed": "2026-06-09", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "5.07 Submission of Matters to a Vote of Security Holders", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1704287/000121390026066896/0001213900-26-066896-index.htm" }, { "form": "8-K", "filed": "2026-06-08", "items": [ "1.01 Entry into a Material Definitive Agreement", "3.02 Unregistered Sales of Equity Securities", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1704287/000121390026066364/0001213900-26-066364-index.htm" } ], "events12m": 19, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001704287.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1704287" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up Bluejay Diagnostics, Inc. ($BJDX). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-08. 19 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2022-12-31", "revenue": 249040, "revenueGrowth1y": null, "revenueGrowthPerYear": null, "yearsOfData": 1, "operatingMargin": -37.414776742691934, "operatingMarginPrior": null, "netMargin": -37.33114359139094, "operatingCashFlow": -7741593, "capitalSpending": 1199270, "freeCashFlow": -8940863, "researchAndDevelopment": 4152152, "researchShareOfRevenue": 16.67263090266624, "cash": 10114990, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2022-12-31", "revenue": 249040 } ], "totalEquity": 11541273, "totalAssets": 13521265, "equityRatio": 0.8535645888162091, "returnOnEquity": -0.8055392156480485, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": null, "ifPaceHeld": null }, "edgarette": "🔖 Exposure: revenue $249K (FY2022). Experience: one year on record; operating margin -3741.5%. Soundness: equity 85.4% of assets, return on equity -80.6%. Credibility: one audited year, little weight. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -3741.5% against a 1.2% median.", "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "summary": "Bluejay Diagnostics (BJDX) reported revenue of $0 million in FY2022, operating margin -3741% against a 1.2% median for surgical & medical instruments & apparatus, equity 85.4% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Bluejay Diagnostics, Inc. against its own record and its peers
Operating marginPeer median 1.2%-3741.5%Equity of assetsPeer median 52.9%85.4%Return on equityPeer median -2.3%-80.6%Gold tick: the median of 55–59 peers with $50M+ revenue in surgical & medical instruments & apparatus
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Bluejay Diagnostics (BJDX) reported revenue of $0 million in FY2022, operating margin -3741% against a 1.2% median for surgical & medical instruments & apparatus, equity 85.4% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2022-12-31", "revenue": 249040, "totalDebt": null, "cash": 10114990 }, "experience": { "revenueGrowth1y": null, "revenueGrowthPerYear": null, "operatingMargin": -37.414776742691934, "operatingMarginPrior": null, "netMargin": -37.33114359139094, "freeCashFlow": -8940863 }, "soundness": { "equityRatio": 0.8535645888162091, "returnOnEquity": -0.8055392156480485, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "credibility": { "auditedYears": 1, "weight": "little", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": null, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001704287.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1704287" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }